Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fujian South Pharmaceutical is a leading commercial manufacturer of oncology APIs such as paclitaxel and docetaxel. Its APIs are approved by major global regulatory agencies, and it holds numerous patents for processing taxanes and related compounds. The company is the largest commercial producer of Taxus-derived APIs in China, with significant international exports. No evidence of internal clinical drug development or proprietary clinical-stage therapeutics was found, as the business is focused on APIs and intermediates approved for finished dosage product manufacturing globally.[1][3][5][7][9]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fujian South Pharmaceutical.